Bookmark

Add to MyYahoo RSS

Hepatitis News

News on Hepatitis continually updated from thousands of sources around the net.

46 min ago | Scientific American

Hepatitis C Drugs Not Reaching the Poor

Discovered in 1989, HCV infects an estimated 185 million people worldwide, more than 80% of whom live in low- and middle-income countries.

Comment?

Related Topix: Medicine, Health, Knowledge Management, HIV/AIDS, Biotech, Gilead Sciences, Healthcare Industry, Foster City, CA, Malaria

4 hrs ago | HIV and Hepatitis

EASL 2014: Sofosbuvir + Ribavirin Safe and Effective for Hepatitis C...

Sofosbuvir plus ribavirin is a safe option that can lead to sustained response for people with advanced liver disease including those with decompensated cirrhosis and portal hypertension and patients who experience severe hepatitis recurrence after a liver transplant, researchers reported last week at the 49thEASL International Liver Congress in ... (more)

Comment?

Related Topix: Medicine, Beth Israel Deaconess Medical Center, Hospital Administration, Healthcare Industry

9 hrs ago | Aidsmap

Adding interferon to nucleoside antivirals may improve response for people with chronic hepatitis B

Our award-winning series of patient information booklets. Each title provides a comprehensive overview of one aspect of living with HIV.

Comment?

Related Topix: Medicine, Health, HIV/AIDS

11 hrs ago | Bellingham Herald

NC officials urge caution after Hepatitis A cases

The warning comes as officials help Mecklenburg and Cabarrus counties respond after a case of Hepatitis A in a food handler.

Comment?

Related Topix: Medicine, Health, Centers for Disease Control and Prevention

12 hrs ago | Information Technology

Research and Markets: Twinrix (Prophylactic Hepatitis B Virus...

Twinrix [Hepatitis A & Hepatitis B Vaccine] is GSK's bivalent combination vaccine that protects children, adolescents, and adults against disease caused by HAV and acute and chronic infections caused by all known strains of HBV.

Comment?

Related Topix: Medicine, Health, Vaccinations, Science / Technology, Cloud Computing

Tue Apr 15, 2014

Stanford

Mice with human livers would have saved lives if used in toxicology testing, study shows

Gary Peltz helped bioengineer a line of mice whose livers were largely replaced with human liver cells, giving researchers a better model for assessing whether drugs might be toxic to human livers.

Comment?

Related Topix: Medicine, Pharmacology, Health, Stanford University

The Motley Fool

How Much Has Merck Shaken Up the Hepatitis C Race?

Now the question seems to be shifting to just how much share rivals like AbbVie showed a 98% SVR12 in genotype-1, treatment-naive patients.

Comment?

Related Topix: Medicine, Health

Infection Control Today

Mechanism Helps Explain Persistence of Hepatitis C Virus

Researchers at the University of California, San Diego School of Medicine have identified a mechanism that explains why people with the hepatitis C virus get liver disease and why the virus is able to persist in the body for so long.

Comment?

Related Topix: UC San Diego

ThinkProgress

'Major Breakthrough' In Hepatitis C Treatment Is Way Too Expensive For Anyone To Afford

Solvadi, a new drug that can help combat hepatitis C, is being hailed as a " turning point " in the treatment of the liver disease.

Comment?

Related Topix: Health, Medicine, Gilead Sciences, Biotech, Healthcare Industry, Startups, US News, US House of Representatives, Democrat, US Politics, Henry Waxman, Frank Pallone, Diana DeGette

News12.com

Health dept. offers vaccines amid hepatitis scare

The Health Dept will offer free Hepatitis A vaccines to restaurant patrons and employees starting Saturday, April 12 from 11 a.m.-5 p.m., Sunday, April 13 from 11a.m.-3 p.m. and Monday, April 14 from 9 a.m.-12 p.m. at the Rockland County Fire Training Center, 35 Firemens Memorial Drive in Pomona 845-364-2997 NYACK - The Rockland County Health ... (more)

Comment?

Related Topix: Health, Rockland County, NY, Pomona, NY, Nyack, NY, Vaccinations

Aidsmap

AbbVie 3-drug combination cures 92%-96% of cirrhotic hepatitis C patients

The largest study of new direct-acting antivirals yet conducted in hepatitis C genotype 1 patients with compensated cirrhosis has shown that it is possible to cure between 92% and 96% of patients with cirrhosis, regardless of previous treatment history, within 12 to 24 weeks, according to results of the TURQUOISE-II study presented at the ... (more)

Comment?

Related Topix: Medicine, Health

Mon Apr 14, 2014

HIV and Hepatitis

EASL 2014: Adding Interferon to Antivirals May Improve Response for Hepatitis B Patients

Adding pegylated interferon to entecavir led to greater HBV viral load decline and higher likelihood of serological response in HBeAg positive chronic hepatitis B patients, but adding interferon after a short course of antivirals did not appear to improve response, according to a set of studies presented at the 49thEASL International Liver Congress ... (more)

Comment?

Related Topix: Medicine, Health

Fox 23

FAQ: The High Cost of Hepatitis C Drugs

April 14, 2014 -- Last week, the World Health Organization strongly endorsed two new oral drugs that fight hepatitis C, a liver -damaging virus.

Comment?

Related Topix: Medicine, Health, Liver Cancer

Lincoln Daily News

Texas Medicaid holds off on proposed limits for Gilead hepatitis drug

T exas is reconsidering whether to impose strict limits on Gilead Sciences' $84,000 hepatitis C treatment for patients on the state's Medicaid health plan for the poor, at the urging of outside advisers, a state official said on Friday.

Comment?

Related Topix: Texas Government, Texas, Medicaid, Health, Biotech, Gilead Sciences, Healthcare Industry

HIV and Hepatitis

EASL 2014: Chinese Herbal Compound Inhibits Hepatitis C Virus Replication

Saturday 12 April 2014 -- Data from a late-breaking abstract presented at the International Liver Congress 2014 identifies a new compound, SBEL1, that has the ability to inhibit hepatitis C virus activity in cells at several points in the virus' lifecycle.

Comment?

Related Topix: Liver Cancer

RedOrbit

Hepatitis C Treatment Without The Side Effects Of Interferon

A new orally-administered antiviral therapy has reportedly cured hepatitis C infection in over 90 percent of patients with liver cirrhosis , according to research published Saturday in the New England Journal of Medicine .

Comment?

Related Topix: Medicine

WYFF-TV Greenville

1,000 get shots after pizza place employee gets hepatitis

Once you're logged in, at the top of each article, video or slideshow you will see a list of your Facebook friends who recently visited Choose to share stories you'e read with your friends or turn sharing OFF to keep your reading experience anonymous .

Comment?

Related Topix: Medicine, Health, Vaccinations, Charlotte, NC, Mecklenburg County, NC, Cabarrus County, NC

CBS Local

More Than 1,000 Get Hepatitis A Shots In Charlotte

Health officials say more than 1,000 people have been given vaccinations against hepatitis A after an employee at a Charlotte pizza restaurant was hospitalized with the disease.

Comment?

Related Topix: Charlotte, NC, Medicine, Health, Vaccinations, Mecklenburg County, NC, Cabarrus County, NC

Wall St. Cheat Sheet

Can Merck, Bristol-Myers, or AbbVie Compete with Gilead's Cure for Hepatitis C?

The race for a hepatitis C cure is closing in fast; Bristol-Myers Squibb Co. and Merck & Co.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Health, Healthcare Industry, Merck , Bristol Myers Squibb

Aidsmap

Sofosbuvir/ledipasvir coformulation cures more than 90% of...

A coformulation of sofosbuvir and ledipasvir taken for as little as 8 weeks produced high sustained response rates across the board for participants in the phase 3 ION trials, including people with HCV genotype 1 starting treatment for the first time, prior non-responders and people with liver cirrhosis, according to findings presented last week at ... (more)

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Food and Drug Administration, Health

•••
•••
•••
•••
•••
•••
•••
•••
•••